


FASTFACTS

A closed, modular approach to autologous CAR T cell therapy manufacturing

Jason Isaacson, Scientist, Thermo Fisher Scientific

The complex, multi-step process of generating functional CAR T cells includes cell isolation, activation, modification, expansion and finally cryopreservation. Introducing closed processes to replace manual manipulations can reduce contamination, errors, and variability. Closed, modular, automatable instrumentation for specific unit operations within the workflow can improve upon consistency, purity and safety of the final CAR T product. Additionally, scalable and compliant platforms support the transition from early discovery to commercial scale manufacturing.

This demonstration provides in-depth understanding of Thermo Fisher Scientific's digitally compatible, GMP-compliant manufacturing platform to produce CAR T cells.



Cell & Gene Therapy Insights 2022;
8(8), 1045; DOI: 10.18609/cgti.2022.154

Copyright © 2022 Thermo Fisher Scientific. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

In collaboration with

ThermoFisher
SCIENTIFIC

 **CELL & GENE THERAPY INSIGHTS**